Related Experiment Video
Updated: Mar 11, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Itraconazole-induced thrombocytopenia
Berna Aksoy1,2
1a Bahcesehir University, Faculty of Medicine, Department of Dermatology , Istanbul , Turkey , and.
Abstract:
Itraconazole is one of the systemic treatment options for extensive tinea versicolor. A male patient who developed thrombocytopenia during the treatment of tinea versicolor by itraconazole is reported in this manuscript. He was diagnosed to develop thrombocytopenia on the third day of treatment. In the literature, there are two reports of itraconazole-induced thrombocytopenia both in malignancy patients. One report contained three patients who developed thrombocytopenia as a result of a drug interaction between bortezomib and itraconazole. The other report contained a patient who developed thrombocytopenia following six weeks of treatment with itraconazole. It is hypothesized by the author of this manuscript that this patient's thrombocytopenia developed as a result of selective bone marrow suppression which is brought about by itraconazole's effect on megakaryocytes.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Therapeutic Drug Monitoring: Affecting Factors
Drugs for Treatment of Ulcerative Colitis in IBD
Pharmacokinetics: Drug–Drug Interactions
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

